Executive committee

Fabrizio Greco - AbbVie
President

President of Assobiotec for 2022-2025. General Manager of Abbvie Italy since 2013 and of Abbott PPD since 2011. Past president of the IAPG (American Pharmaceutical group industry Association).
He began his career in 1991 as Financial Analyst at Ely Lilly and in 1994, after the split of the Medical Devices and Diagnostic division of Eli Lilly (that created Guidant), he was appointed Finance and  HR manager of Guidant Italy. During the years he covered commercial roles of increasing responsibilities including General Manager Guidant Portugal in 2002 and General Manager Abbott Vascular Italy in 2006. Education: Degree in Electronic Engineering from the University of Genova and Master’s degree in Business Administration from the Bocconi University of Milan.  

Elena Sgaravatti - PlantaRei Biotech
Vice President

Elena Sgaravatti is PlantaRei President, Co-founder and shareholder of Demethra Biotech Srl. After graduating with a Pharm. D. degree from Padova University, she developed more than twenty years of experience in the pharmaceutical sector, from business development to strategic marketing in multinational companies such as GSK. She was CEO at IRB Spa (Biotechnological Research Institute) until June 2016, a company she launched in 2009, when she joined as General Director, which was acquired by Croda Int. Plc, in 2012. In 2016 she founded, together with Cereal Docks Group, Demethra Biotech S.r.l., an innovative start-up of green biotech. She is the inventor of eleven patents, she is member  of the Academic Commission of the University of Medical Biotechnology of Modena and as well as of the Scientific Committee of the Cluster Bioinnova (Biological Cluster Veneto). She has been a member of the working group for the accreditation and evaluation of the Master’s Degree Program in Biotechnology for Food at the Agripolis University of Padua since 2019. Winner of  #GreenBiotech Award Tecnovisionarie 2020.

Ugo Gay - DiaSorin Italia
Vice President

Ugo Gay is Senior Vice President Industrial Operations in DiaSorin. Born in 1965, he began his career in 1985 in the family business. In 1995 he moved to the Istituto Biologico Chemioterapico di Torino (Chemotherapy Biological Institute), where in 1998 he held the position of Chief Executive Officer in a company of the group. He joined DiaSorin in 2000 as Sales Director for the Italian market, holding various positions within the Group: Managing Director of the JV between DiaSorin and Byk Sangtec (2002), Country Manager - Italy and General Manager - Iberia and Czech Republic (2003- 2009) and VP Commercial Operations for Europe and Africa (2009-2012). In the same period, he is also member of the board of Assobiomedica and of the European Association of Diagnostics (EDMA), with the role of Vice President.
From 2012 he continues his career in DiaSorin’s Industrial Operations (Europe and Africa). In 2019 he is appointed Senior Vice President of Industrial Operations, at a corporate level, a position he still holds.

Federico Viganò - Vertex Pharmaceutical
Member

Federico Viganò is Country Manager for Italy and Greece of Vertex Pharmaceuticals. He has a CTF degree from the University of Milan, an Executive MBA from Imperial College London and a master's degree in Chinese history from Trinity College Dublin. After ten years experience, in Italy and abroad, in the GSK vaccine area, he worked in Astrazeneca as Vice President in the cardiovascular and respiratory areas and then as Country President for Ireland.

Pierluigi Paracchi - Genenta Science
Member

Pierluigi Paracchi is an experienced venture capital investor, Founder and CEO of Quantica SGR, co-founder of Axòn Capital and AurorA Science and previously Venture Consultant at Sofinnova Partners. He was also an investor in and Board Member of Ethical Oncology Science, which was acquired in 2013 in a total deal of $400+ million. He also serves as non-executive Director of the autoimmune disease company Altheia Science, non-executive Chairman at Lipogems International (Medical Device for Processing Adipose Tissue).

Riccardo Palmisano - DiaSorin Italia
 Past President

Riccardo Palmisano is currently Board Member at Agc Biologics SpA, Chairman of the Board at BetaGlue, Industry Board Member for an undisclosed Investment Fund, Advisor for DiaSorin, EIM and Frezza&Partners. Graduated in Medicine at Parma University,  his career in the Italian pharmaceutical industry started in 1986 at Farmitalia Carlo Erba (1986). He then moved to the Menarini Group (1988) where he contributed to the development and internationalization of the first Italian pharmaceutical Group, becoming Head of the Pharmaceutical Division Italy in 1993 and General Manager at Lusofarmaco in 1995. His career in multinational companies started in 2000, when he set up the Italian branch of Shire Pharmaceutical; in 2003 he was appointed Vice President Commercial Retail Market at GlaxoSmithKline Verona and then he served since 2005 as Vice President & General Manager Italy at Genzyme, a U.S. biotech company specialized in research and development of orphan drugs for rare diseases. After the acquisition of Genzyme by Sanofi he was also appointed Director of Business Strategy and Development at Sanofi Italia (2012-2014). From 2015 to and 2020 he held the position of CEO of MolMed, a cell&gene listed company, now part of Agc Biologics. During his career, he successfully launched a large number of important products in many therapeutic areas, in both retail and hospital markets, participated and supported several international projects, and successfully negotiated pricing and reimbursement for several innovative drugs with both Italian and European Authorities. In 2008, he joined Assobiotec, becoming Vice President in 2010. In 2016, was appointed President of Assobiotec and then re-elected in 2019. He is also Vice President of the Lombardy Life Sciences Cluster at Assolombarda.